Navigation Links
AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
Date:10/29/2010

sed to bring the first proven treatment option to the many patients in the U.S. living with PBA.  I would like to thank FDA for working closely with us to make NUEDEXTA available."

"PBA is a disabling neurologic condition commonly found in patients with underlying neurologic diseases or injuries. These patients frequently experience embarrassment due to their unpredictable emotional outbursts, leading to disruption of their interpersonal relationships and social isolation," said Erik P. Pioro, MD, PhD, FRCPC, Director of the Section for ALS and Related Disorders at the Cleveland Clinic in Cleveland, Ohio and an investigator in clinical studies evaluating NUEDEXTA. "As a physician who has cared for many patients with PBA, I am pleased that there is now a safe and effective treatment option for PBA that may help these patients regain more control over their daily lives and live with dignity."

NUEDEXTA is a first-in-class medication that acts on sigma-1 and NMDA receptors in the brain, although the exact mechanism by which NUEDEXTA exerts therapeutic effects in patients with PBA is unknown. Studies to support the effectiveness of NUEDEXTA were performed in patients with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).  NUEDEXTA has not been shown to be safe and effective in other types of emotional lability that can commonly occur, for example, in Alzheimer's disease and other dementias.

The primary outcome measure, laughing and crying episodes, was significantly lower in the NUEDEXTA arm compared to placebo.  The secondary outcome measure, the Center for Neurologic Studies Lability Scale (CNS-LS), demonstrated a significantly greater mean decrease in CNS-LS score from baseline for the NUEDEXTA arm compared to placebo.

Conference Call

AVANIR will hold a conference call and audio webcast on November 1, 2010 at 8:15 a.m. To participate in the conference call, please dial 877-558-3407 (domestic) o
'/>"/>

SOURCE AVANIR Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
2. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... -- Research and Markets has announced ... (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market - ... On the basis of type ... been divided into eight major segments, namely, light/laser, ... ablation technologies. The light/laser ablation technology segment accounted ...
(Date:9/22/2014)... , Sept. 22, 2014  Olympus, a ... solutions for medical and surgical procedures, among other ... deal with Munich -based Brainlab ... ® Navigation. This agreement applies to the ... cross-disciplinary U.S. sales and all distribution outside the ...
(Date:9/22/2014)... 22, 2014  Sutro Biopharma today announced that it ... of 2014,s Fierce 15 biotechnology companies, designating it as ... the industry.  "Sutro has earned some ... well as industry partners for what promises to be ... says John Carroll , editor of FierceBiotech ...
Breaking Medicine Technology:Global Ablation Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market - Forecasts to 2019 2Global Ablation Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market - Forecasts to 2019 3Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 2Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 3Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 4FierceBiotech names Sutro Biopharma as one of its "Fierce 15" Biotech Companies of 2014 2FierceBiotech names Sutro Biopharma as one of its "Fierce 15" Biotech Companies of 2014 3
... the "NEXT" Study Also Showed Arzoxifene Significantly Suppressed ... with OsteoporosisATHENS, Greece, March 23 Eli Lilly ... new data showing arzoxifene, an investigational selective estrogen ... increasing bone mineral density (BMD) in the lumbar ...
... Santaris Pharma announced today that,the fourth LNA-based drug ... USA,several patients with cancer have now been treated ... by Santaris Pharma and Enzon,Pharmaceuticals. The U.S. Food ... New Drug (IND) application,for the use of the ...
Cached Medicine Technology:Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 2Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 3Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 4Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 5Another LNA-based RNA Inhibitor Enters Clinical Trials 2Another LNA-based RNA Inhibitor Enters Clinical Trials 3
(Date:9/22/2014)... News) -- Teens and young adults at risk for ... help prevent risky sexual behaviors, according to new recommendations ... year, about 20 million new sexually transmitted infections such ... About half involve people between 15 and 24 years ... new report, published Sept. 22 in Annals of ...
(Date:9/22/2014)... pulls back the curtain on one of the most ... income between physicians who perform operations, procedures or tests, ... the research indicates, the physician payment system is not ... , The new findings counter the widely held belief ... why doctors who perform procedures often earn nearly twice ...
(Date:9/22/2014)... Manhattan residents who suffer with hip ... hip , which could be bursitis now have a ... now offered at New York Dynamic Neuromuscular Rehabilitation Center. ... occurs when the trochanteric bursa becomes irritated or inflamed. ... between the iliotibial band and the greater trochanter. Most ...
(Date:9/22/2014)... Steven Reinberg HealthDay Reporter ... urging that all children aged 6 months and older be ... of Pediatrics updated their influenza vaccine recommendations to advise that ... to build immunity. The AAP also wants parents of children ... nasal spray vaccine instead of the flu shot if it,s ...
(Date:9/22/2014)... 40 percent of patients undergoing breast cancer surgery require ... the cancerous tissue in the initial operation. However, researchers ... a tool they developed that will help surgeons better ... the chances for repeat operations. , ... 22, 2014 in the Proceedings of the National ...
Breaking Medicine News(10 mins):Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 2Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 3Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 2Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 3Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 4Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 2Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 3Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 2Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 3Health News:The fine line between breast cancer and normal tissues 2
... In India the only laboratory equipped to handle the avian ... Tiny vials of chicken blood and poultry tissue arrive each ... by the farmers from places that experience unusual chicken deaths ... Hare Krishna Pradhan, who heads the High Security Animal Disease ...
... always pleasurable to the eye and so are coloured veggies ... led by Dr. Isabelle Romieu of the National Institute of ... women consuming plenty of tomatoes, carrots and leafy greens appear ... per a report in the medical journal Thorax. Still, it's ...
... insomnia or loss of sleep affects finding way around negatively. ... is difficulty finding the way around.// ,This was tried ... rats' spatial memory was affected. ,Still, experts at UK ... the Journal of Neurophysiology. ,Two groups of rats were studied, ...
... Speculation that the Food and Drug Administration will give ... shares in ViroPharma to dip by about 33 percent. ... after Laura Alvey, a spokeswoman for the F.D.A said ... revised the bioequivalence recommendations for oral vancomycin from a ...
... are angry at the village heads, which has issued orders ... threatened to go on an indefinite strike unless the order ... directed district chief medical officers to take the attendance of ... the help of village chiefs or other local officials. ...
... is recovering well, after a cancer unit administered a potentially ... life, and is currently receiving specialist oxygen treatment. // She ... soon. ,Lisa Norris from Girvan in Ayrshire, ... overdose 17 times at the Beatson Oncology Centre in Glasgow. ...
Cached Medicine News:
Designed to meet the requirements of reagent grade water for routine analysis....
... L/min of Type I ultrapure water, , ... Plus System is designed to provide the ... pretreated by reverse osmosis, distillation or deionization. ... quality which exceeds Type I ASTM/CAP/NCCLS specifications.,The ...
... Basic Laboratory Needs, Synergy systems produce ultrapure water ... 1 to 1.2 L/min to meet the basic ... incorporates a dual-wavelength UV lamp (185 nm and ... of organic contaminants (< 5 ppb TOC when ...
... Compact System Produces Type I Water Directly from ... designed for scientists who need 5 to 15 ... not have easy access to acceptable quality pretreated ... 0.6 L/min of ultrapure (Type I) water on ...
Medicine Products: